MiNK Therapeutics (NASDAQ:INKT) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of MiNK Therapeutics (NASDAQ:INKT) in a report released on Friday,Benzinga reports. They currently have a $9.00 price objective on the stock. HC Wainwright also issued estimates for MiNK Therapeutics’ FY2028 earnings at $0.24 EPS.

Separately, Robert W. Baird lowered their target price on shares of MiNK Therapeutics from $8.00 to $4.00 and set an “outperform” rating for the company in a research note on Friday.

MiNK Therapeutics Trading Down 7.8 %

Shares of INKT opened at $0.70 on Friday. The stock has a market cap of $27.48 million, a P/E ratio of -1.78 and a beta of 0.05. MiNK Therapeutics has a 1 year low of $0.57 and a 1 year high of $1.90. The stock’s 50-day moving average price is $0.73 and its two-hundred day moving average price is $0.85.

Institutional Investors Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Renaissance Technologies LLC raised its position in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 127,841 shares of the company’s stock after acquiring an additional 22,613 shares during the period. Renaissance Technologies LLC owned about 0.37% of MiNK Therapeutics worth $121,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.